Table 1 Patients’ characteristics

Age (years)

78(69–86)

75(65–83)

0.29

Males n (%)

7(54)

8(50)

1.00

Hypertension n (%)

9(69)

10(63)

1.00

Diabetes mellitus n (%)

5(38)

4(25)

0.69

Source of infection

Lungs n (%)

6(46)

10(63)

0.47

Abdomen n (%)

7(54)

4(25)

0.14

Soft tissue n (%)

0(0)

1(6)

1.00

Other n (%)

0(0)

1(6)

1.00

APACHE score II

24(24–30)

23(19–27)

0.13

SOFA score

11(10–12)

11(8–12)

0.19

Mechanical ventilation n (%)

10(77)

13(81)

0.70

Norepinephrine (ug/kg/min)

0.3(0.1-0.4)

0.2(0.2-0.4)

0.36

Fluid Therapy

 Hydroxyethyl starch n (%)

8(62)

7(44)

0.46

 Colloid fluid n (%)

11(85)

13(81)

1.00

 Hydroxyethyl starch amount (ml/kg)

11.7(7.1-18.6)

7.9(7.1-10.0)

0.20

 Colloid fluid amount (ml/kg)

13.8(7.1-20.0)

8.2(5.0-10.6)

0.20

 Crystalloid fluid amount (ml/kg)

26.8(15.7-34.7)

28.3(18.9-42.8)

0.51

 Resuscitation fluid amount(ml/kg)

35.8(27.6-53.6)

36.1(25.8-52.4)

0.86

EGDT period (hour)

6.0(6.0 -7.0)

6.0(5.0-6.0)

0.27

Poor renal outcome n (%)

8(62)

1(6)

0.003

 AKI 2-3on admission n (%)

6(46)

4(25)

0.27

 Persistent AKI n (%)

4(31)

1(6)

0.14

 AKI 0-1on admission n (%)

7(54)

12(75)

0.27

 New AKI n (%)

2(15)

0(0)

0.19

Use of renal-replacement therapy n (%)

6(46)

3(19)

0.23

Days in ICU (days)

8(6–14)

8(7–19)

0.98

28-day mortality n (%)

6(46)

5(31)

0.47